VOR Vor Biopharma

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021. Robert Ang, MBBS, MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are scheduled to present on Thursday, March 4, 2021, at 1:30 p.m. E.T.

About Vor Biopharma

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

Contacts:

Investor:

Constantine Davides, CFA

Westwicke



Media:

Mary Carmichael

Ten Bridge Communications





EN
01/03/2021

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Infla...

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1Location: Virtual A live webcast and archived replay of the fireside chat will be available on the Company’s we...

September 12, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growth CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. “We are delighted to welcome Adi to Vor...

September 2, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for I...

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy Results reinforce telitacicept’s potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults wi...

August 27, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School ConferenceFireside Chat: Tuesday, September 2nd, 2025, at 11:15am ETLocation: Boston, MA A live webcast and archived replay of the fireside chat will be available on the investors section of . Baird 2025 Global Healthcare Conference 1x1 Investor...

August 26, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August 4, 2025, and August 18, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 6,959,013 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,491,217 shares of Vor Bio’s common stock to seven newly hi...

August 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch